CICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps "Outperform" Rating

Stock News03-23

CICC has released a research report indicating a reduction in its net profit forecasts for GIANT BIOGENE (02367) for 2026 and 2027 by 10% each, to 1.92 billion and 2.15 billion yuan respectively. This adjustment is based on anticipated external headwinds and heightened competition. The firm maintains an "Outperform" rating on the stock. Reflecting the revised earnings projections and shifts in sector valuation benchmarks, the target price has been lowered by 13% to HK$49.

GIANT BIOGENE's 2025 financial results aligned with the institution's expectations. Revenue reached 5.52 billion yuan, representing a slight decrease of 0.4% year-on-year. Net profit was 1.92 billion yuan, down 7.2% compared to the previous year. On an adjusted basis, net profit stood at 1.96 billion yuan, declining by 8.9% year-on-year. The company also announced a final dividend of 0.54 yuan per share and a special dividend of 0.67 yuan per share for 2025, resulting in a total dividend payout ratio of 67%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168613956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 14:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168613956","market":"hk","top_or_hot":-1,"title":"CICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps \"Outperform\" Rating","media":"Stock News","content":"<p>CICC has released a research report indicating a reduction in its net profit forecasts for GIANT BIOGENE (02367) for 2026 and 2027 by 10% each, to 1.92 billion and 2.15 billion yuan respectively. This adjustment is based on anticipated external headwinds and heightened competition. The firm maintains an \"Outperform\" rating on the stock. Reflecting the revised earnings projections and shifts in sector valuation benchmarks, the target price has been lowered by 13% to HK$49.</p>\n<p>GIANT BIOGENE's 2025 financial results aligned with the institution's expectations. Revenue reached 5.52 billion yuan, representing a slight decrease of 0.4% year-on-year. Net profit was 1.92 billion yuan, down 7.2% compared to the previous year. On an adjusted basis, net profit stood at 1.96 billion yuan, declining by 8.9% year-on-year. The company also announced a final dividend of 0.54 yuan per share and a special dividend of 0.67 yuan per share for 2025, resulting in a total dividend payout ratio of 67%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps \"Outperform\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps \"Outperform\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-23 14:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CICC has released a research report indicating a reduction in its net profit forecasts for GIANT BIOGENE (02367) for 2026 and 2027 by 10% each, to 1.92 billion and 2.15 billion yuan respectively. This adjustment is based on anticipated external headwinds and heightened competition. The firm maintains an \"Outperform\" rating on the stock. Reflecting the revised earnings projections and shifts in sector valuation benchmarks, the target price has been lowered by 13% to HK$49.</p>\n<p>GIANT BIOGENE's 2025 financial results aligned with the institution's expectations. Revenue reached 5.52 billion yuan, representing a slight decrease of 0.4% year-on-year. Net profit was 1.92 billion yuan, down 7.2% compared to the previous year. On an adjusted basis, net profit stood at 1.96 billion yuan, declining by 8.9% year-on-year. The company also announced a final dividend of 0.54 yuan per share and a special dividend of 0.67 yuan per share for 2025, resulting in a total dividend payout ratio of 67%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"","article_id":"1168613956","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168613956","pubTimestamp":1774247067,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CICC has released a research report indicating a reduction in its net profit forecasts for GIANT BIOGENE (02367) for 2026 and 2027 by 10% each, to 1.92 billion and 2.15 billion yuan respectively....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1207":"个人用品","02367":"巨子生物","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD"},"translate_title":"中金下调巨头百奥基因(02367)目标价至49港元维持“跑赢大市”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"CICC has released a research report indicating a reduction in its net profit forecasts for GIANT BIOGENE (02367) for 2026 and 2027 by 10% each, to 1.92 billion and 2.15 billion yuan respectively. This adjustment is based on anticipated external headwinds and heightened competition. The firm maintains an \"Outperform\" rating on the stock. Reflecting the revised earnings projections and shifts in sector valuation benchmarks, the target price has been lowered by 13% to HK$49.\nGIANT BIOGENE's 2025 financial results aligned with the institution's expectations. Revenue reached 5.52 billion yuan, representing a slight decrease of 0.4% year-on-year. Net profit was 1.92 billion yuan, down 7.2% compared to the previous year. On an adjusted basis, net profit stood at 1.96 billion yuan, declining by 8.9% year-on-year. The company also announced a final dividend of 0.54 yuan per share and a special dividend of 0.67 yuan per share for 2025, resulting in a total dividend payout ratio of 67%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168613956","isCrawlerRequest":true}